Clinical Trial

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.
Protocol Amendment History 2 changes
notable Trial sites expanded: 84 -> 88 locations 2026-07-31
notable Trial sites expanded: 75 -> 81 locations 2026-04-23
Trial Details
NCT Number NCT07039916
Lead Sponsor Immunovant Sciences GmbH
Conditions Generalized Myasthenia Gravis
Enrollment 231 participants
Start Date 2025-05-27
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-30